Cerenome, Inc. entered into a Securities Purchase Agreement on September 4, 2026, for a senior secured convertible note financing with an aggregate original principal amount of $21,276,596. The initial closing is expected on or about September 10, 2026, yielding gross proceeds of approximately $3,000,000. The notes carry an 8% annual interest rate, a 6% original issue discount, and convert into common stock at an initial price of $2.74 per share. A royalty agreement requires the subsidiary CNSide to pay quarterly royalties equal to 2.5% of gross revenues, capped at 2.5% of the outstanding note balance. The company intends to use net proceeds for working capital and general corporate purposes. Cerenome operates in the biotechnology industry, developing precision diagnostics and targeted therapeutics for central nervous system oncology.